Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07227402 · ClinicalTrials.gov registry record · Phase 3
A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6482-033)
A Phase 3 study, sponsored by Merck Sharp & Dohme.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 904
- Enrollment target
NCT07227402 is a Phase 3 study that is actively recruiting participants, run by Merck Sharp & Dohme. The registered enrollment target is 904 participants.
The verdict
NCT07227402, a Phase 3 study, is actively recruiting participants, sponsored by Merck Sharp & Dohme.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 904 participants
- Enrollment target
Study Summary
Researchers are looking for more ways to treat advanced renal cell carcinoma (RCC) that is recurrent. Researchers want to learn if recurrent advanced renal cell carcinoma (RCC) responds (gets smaller or goes away) after treatment with belzutifan (MK-6482) and zanzalintinib compared to cabozantinib. The goal of this study is to learn if: People who take belzutifan and zanzalintinib live longer overall and without the cancer getting worse than people who take cabozantinib.
Interventions
- DRUG Belzutifan
- DRUG Zanzalintinib
- DRUG Cabozantinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 904 participants |
| Start Date | 2025-11-26 |
| Est. Completion | 2032-02-27 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07227402
The ClinicalTrials.gov registry entry for NCT07227402 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 904 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Merck Sharp & Dohme, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Belzutifan is the first listed.
NCT07227402 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07227402 about?
NCT07227402 is a clinical study titled "A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6482-033)". Researchers are looking for more ways to treat advanced renal cell carcinoma (RCC) that is recurrent. Researchers want to learn if recurrent advanced renal cell carcinoma (RCC) responds (gets smaller or goes away) after treatment with belzutifan (MK-6482) and zanzalintinib compared to cabozantinib. ...
What is the current status of trial NCT07227402?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 904 participants. The study started on 2025-11-26. Estimated completion is 2032-02-27.
What interventions are being tested in trial NCT07227402?
The interventions under investigation include: Belzutifan (DRUG), Zanzalintinib (DRUG), Cabozantinib (DRUG).
Who is sponsoring clinical trial NCT07227402?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.